RANTES in onchocerciasis: changes with ivermectin treatment
| Autor: | Philip J. Cooper, D. W. Taylor, D. Prakash, Thomas B. Nutman, I. Espinel, R. H. Guderian, Daniel G. Remick, George E. Griffin |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male Chemokine Adolescent medicine.medical_treatment Immunology Onchocerciasis Pathogenesis medicine Humans Immunology and Allergy Eosinopenia Interleukin 8 Child Chemokine CCL5 Aged Ivermectin biology Interleukin-6 Tumor Necrosis Factor-alpha business.industry Interleukin-8 Original Articles Middle Aged Eosinophil biology.organism_classification medicine.disease Onchocerca volvulus medicine.anatomical_structure Cytokine biology.protein Female business |
| Zdroj: | Clinical and Experimental Immunology. 106:462-467 |
| ISSN: | 1365-2249 0009-9104 |
| DOI: | 10.1046/j.1365-2249.1996.d01-868.x |
| Popis: | Adverse reactions are seen relatively frequently after treatment of onchocerciasis patients with ivermectin. The chemokines RANTES and IL-8, which have both chemotactic and activation properties for eosinophils and neutrophils, respectively, may have a role in the pathogenesis of post-treatment reactions. Circulating levels of the chemokines and the cytokines tumour necrosis factor-alpha (TNF-α) and IL-6 were measured in the plasma of 22 Onchocerca volvulus-infected subjects. Peaks of mean circulating levels of RANTES and TNF-α were seen at 6 h after ivermectin administration. Peripheral eosinophil counts declined at 36 h post-treatment and an early peak in RANTES levels was associated with a delay in peripheral eosinopenia. RANTES levels were negatively correlated with severity of rash (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|